NW Bio Provides Update About Phase 3 Trial Of DCVax®-L for Newly Diagnosed Glioblastoma Multiforme Brain Cancer
2016-12-08 19:04:51.107 GMT
NW Bio Provides Update About Phase 3 Trial Of DCVax®-L for Newly Diagnosed
Glioblastoma Multiforme Brain Cancer
Trial Enrolled 331 Patients;
Data "Events" Accumulating Towards Trial Endpoints
PR Newswire
BETHESDA, Md., Dec. 8, 2016
BETHESDA, Md., Dec. 8, 2016 /PRNewswire/ -- Northwest Biotherapeutics (Nasdaq:
NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided an update about the Company's Phase 3 trial of DCVax®-L for Glioblastome multiforme (GBM) brain cancer (the "Trial"). The Company announced that 331 of the planned 348 patients have been enrolled in the Trial, and that data "events" have been accumulating towards the endpoints of the Trial.
As noted in the profile of the Trial on www.clinicaltrials.gov, the Company had estimated that the numbers of "events" to reach the main endpoints of the Trial may be reached in November 2016. Following the end of the month last week, the Company requested updates from the external parties managing the Trial about the numbers of "events" (i.e., tumor recurrences or deaths). Such updates typically take a couple of weeks, including quality control checking.
The Company hopes to receive this information and be able to make a further update announcement in approximately the next two weeks. The Company remains blinded in regard to the Trial data and, as before, will only be receiving such updates on a blinded basis.
Since the summer of last year, the trial has been subject to a partial clinical hold, only on recruitment. As a result of the partial hold, the Trial has not enrolled the last 17 of the total 348 patients. To date, the regulators have not agreed to remove the partial hold, but have allowed all of the patients in the Trial to continue being treated in accordance with the Protocol. The Company is pursuing ongoing dialog with regulators. However, at this point the Company believes that the potential benefits that could be obtained from enrolling the final 17 patients would not be worth the time it would take, as the process of re-starting and re-training the sites (including through Institutional Review Board renewals) for further enrollment would take months, followed by further months for the recruitment itself.
Accordingly, the Company is no longer seeking to enroll the last 17 of the 348 patients. Rather, the Company is focused on accumulation of the "events"
necessary for the Trial endpoints. When sufficient "events" have accumulated, the external parties managing the Trial will then begin the process of moving toward "data lock" and then analysis of the data, which are typically each multi-month processes, particularly for large international trials.
News 
Market Data 
Discover 
